Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 5, 2000, Pages 1007-1020

  Culpitt, Sarah V ^a   Rogers, Duncan F ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Anticholinergic; Ariflo ; Bronchodilator; Bupropion; COPD; Corticosteroid; N acetylcysteine; Theophylline; 2 adrenoceptor agonist

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; HUMAN; PATHOPHYSIOLOGY; REVIEW;

CLINICAL TRIALS; HUMANS; LUNG DISEASES, OBSTRUCTIVE;

EID: 0034231457     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.5.1007     Document Type: Article

References (107)

1. SIAFAKAS NM: ERS consensus statement: optimal assessment and management of chronic obstructive pulmonary disease. Enr. Kesp. Review(1996) 6:270-275.
2. European guidelines for management of COPD.
3. ATS: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: American Thoracic Society. Am.]. Respir. Crit. CareMed.
4. 152(SuppI.):S77-S121.
5. American guidelines for management of COPD.
6. HURD S: The impact of COPD on lung health worldwide: epidemiology and incidence. Chest (2000) 117:1S-4S.
7. SULLIVAN SD, RAMSEY SD, LEE TA: The economic burden of COPD. Gbesf (2000) 117ÖS-9S.
8. NATIONAL HEALTH SERVICE EXECUTIVE: Burdens of disease: a discussion document Department of Health (1996).
9. FLETCHER C, PETO R, TINKER C, SPEIZER FE: The natural history of chronic bronchitis and emphysema. An eight year study of early COPD in working men in London. (1976).
10. Definitive epidemiological study linking COPD to cigarette smoking.
11. ANTHONISEN NR, CONNETT JE, KILEY JP et al.: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEVi. The Lung Healtn Study. JAMA (1994) 272:1497-1505.
12. SANDFORD AJ, WEIR TD, PARE PD: Genetic risk factors for chronic obstructive pulmonary disease. Ear. Respir. J. (1997) 10:1380-1391.
13. BARNES PJ: Molecular genetics of COPD. 77jorrtx(1999) 54:245-252.
14. HUANG SL, SU CH, CHANG SC: Tumour necrosis factoralpha gene polymorphism in chronic bronchitis. Am.
15. J. Respir. Crit. Care Meet. (1997) 156:1436-1439.
16. SMITH CA, HARRISON DJ: Association between polymorphism in the gene for microsomal cpoxidc hydrola.se and susceptibility to emphysema. Lancet (1997) 350:630-633.
17. LEBOWITZ MD: Epidemiological studies of the respiratory effects of air pollution. Eur. Respir. J. (1996) 9:1029-1054.
18. STRACHAN DP, SEAGROATT V, COOK DG: Chest illness in infancy and chronic respiratory disease in later life: an analysis by month of birth. Int.J. Epiilemiol. (1994) 23:1060-1068.
19. MATSUSE T, HAYASHI S, KlAVANO K et al.: Latent adenoviral infection in the pathogencsis of chronic airways obstruction. Am. Rev. Respir. Dis. (1992) 146:177-184.
20. BRITTON JR, PAVORD ID, RICHARDS KA et al.: Dietary antioxidant vitamin intake and lung function in the general population. Am.]. Respir. Crit. CareMed. (1995) 151:1383-1387.
21. PARROTT S, GODFREY C, RAW M et al.: Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Thorax (1998) 53(Suppl. 5):Sl-38.
22. Evidence of cost efficacy of smoking cessation.
23. SIAFAKAS N.M, VERMIERE P, PRICE NB et al.: Optimal assessment and management of chronic obstructive pulmonary disease (COPD): The European Respiratory Society Task Force. Enr. Kesp.J. (1995) 8:1398-14 20.
24. BTS guidelines for the management of chronic obstructive pulmonary disease: The COPD Guideline Group of the Standards of Care Committee of the BTS.
25. jomx(1997) 52(Suppl. 5): S1-S28.
26. BAUERLE 0, CHRUSCH CA, YOUNES M: Mechanisms by which COPD affects exercise tolerance. Am. J. Respir. Crit. Care Med. (1998) 157:57-68.
27. O'DONNELL DE: Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest (2000) 117:425-475.
28. GROSS NJ, SKORODIN MS: Anticholinergic, antimuscarinic bronchodilators. Am. Rev. Respir. Dis. (1984) 129:856-870.
29. TAMAOKI J, CHIYOTANI A, TAGAYA E et al.: Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax (1994) 49:545-548.
30. FRIEDMAN M, SERBY CW, MENJOGE SS, WILSON JD, HILLEMAN DE, WITEK TJ: Pharmacoeconomic evaluation of a combination of ipratropium plus albutcrol compared with ipratropium alone and albuterol alone in COPD. Chest (1999) 115:635-641.
31. MAESEN FP, SMEETS JJ, SLEDSENS TJ, WALD FD, CORNELISSEN PJ: Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Ettr. Resptr.J. (1995) 8:1506-1513.
32. CASABURI R, SERBY CW, MENJOGE SS et al.: The spirometric efficacy of once daily dosing with tiotropium In stable COPD. Am.J. Respir. Crit. Care Med. (1999) 159:A524.
33. LITTNER MR, ILOWITE JS, TASHKIN DP et al.: Long-acting bronchodilation with once-daily dosing of tiotropium (spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2000) 161:1136-1142.
34. SHAH P, DHURJON L, METCALFE T, GIBSON JM: Acute angle closure glaucoma associated with nebulised ipratropium bromide and salbutamol. BMJ (1992) 304:40-41.
35. ULRIK CS: Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised,
36. double blind placebo controlled, crossover study. K>orox(1995) 89:750-754.
37. BOYD G, MORICE AH, POUNSFORD JC, SIEBERT M, PESLIS N, CRAWFORD C: An evaluation of salmetcrol in the treatment of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. (1997) 10:815-821.
38. DOWLING RB, JOHNSON M, COLE PJ et al.; Effect of salmetcrol on HaemopbUus influenzae infection of respiratory mucosa in vitro. Eur. Respir. J. (1998) 11:86-90.
39. MOHAMMED AF, ANDERSON K, MATUSIEWICZ SP, BOYD G, GREENING AP, THOMSON NC: Effect of controlledrelease salbutamol in predominantly non-reversible chronic airflow obstruction. Respir. Meet. (1991) 85:495-500.
40. The COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albutcrol together are better than either alone in COPD. Chest (1997) 112:1514-1521.
41. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albutcrol is more effective than cither agent alone. An 85-day multicentcr trial 0>es/(1994) 105:1411-1419.
42. Good evidence for the effectiveness of bronchodilator combination therapy in COPD.
43. CAMPBELL S: For COPD a combination of ipratropium bromide and albutcrol sulfate is more effective than albutcrol base. Arch. Intern. Med. (1999) 159:156-160.
44. IND PW, SANDSTROM T, WALLAERT B, DEAMER L, NYSTROM P, ROCCHICCIOLI K: TolerabUity profile of viozan (AR-C68397AA)i a novel therapy for symptomatic treatment of COPD. Am.]. Respir. Crtt. Care Med. (2000) l6l(Suppl.):A821.
45. WENZEL SE, IND PW, LAURSEN LC, DEAMER L, NYSTROM P, ROCCHICCIOLI K: Viozan (AR-C68397AA) reduces brcathlcssncss, cough and sputum production in COPD patients. Am. J. Respir. Crit. Care Med. (2000) l6l(Suppl.):A490.
46. VAZ FRAGOSO CA, MILLER MA: Review of the clinical efficacy of thcophylline in the treatment of chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. (1993) 147:540-547.
47. MURCIANO D, AUCLAIR M, PARIENTE R, AUBIER M: A randomized, controlled trial of thcophylline in patients with severe chronic obstructive pulmonary disease, ff. Engl.J.Med. (1989) 23:1521-1525-
48. Good evidence for the effectiveness of theophylline in COPD.
49. IRAVANI J, MELVILLE GN: Theophylline and mucociliary function. Chest (1987) 92:S38-S43.
50. KIDNEY J, DOMINGUEZ M, TAYLOR PM, ROSE M, CHUNG KF, BARNES PJ: Immunomodulation by theophylline in asthma. Am. J. Respir. Crit. Care Med. (1995) 151:1907-1914.
51. CULPITT SV, MAZIAK W, LOUKIDIS S, KELLER A, BARNES PJ: Effect of theophylline on induced sputum
52. inflammatory indices in COPD patients. Am.]. Respir. Crit. Care Med. (1998) 157(3):A797.
53. CONDINO-NETO A, VILELA AIMS, CAMBIUCCI EC et al: Theophylline therapy inhibits neutrophil and mononuclcar cell chcmotaxis from chronic asthmatic chUdren. Br.J. Clin. Pharmac. (199D 32:557-561.
54. LLEWELLYN-JONES CG, STOCKLEY RA: The effects of beta 2-agonists and methylxanthincs on neutrophil function in vitro. Etir. Respir. J. (1994) 7:1460-1466.
55. NIELSON CP, VESTAL RE, STURM RJ, HEASLIP R: Effect of selective phosphodiestcrase inhibitors on the polymorphonuclcar leukocyte respiratory burst. J.
56. Allergy Clin. Immimol. (1990) 86:801-608.
57. LACOSTEJY, BOUSQUETJ, CHANEZ P étal.: Eosinophüic and ncutrophilic inflammation in asthma, chronic bronchitis and chronic obstructive pulmonary disease./ Allergy Clin. Immiinol. (1993) 92:537-548.
58. TORPHY TJ, BARNETTE MS, UNDERWOOD DC et a!.: Ariflo (SB 207499), a second generation phosphodiestcrase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulin. Pharmacol. Tber. (1999) 12:131-135.
59. Introduction to a new class of therapeutic compound for treatment of lung inflammation, including COPD.
60. COMPTON CH, GUBB J, CEDAR E et al.: The efficacy of Ariflo (SB 207499), a second generation oral PDE4 inhibitor, in patients with COPD. A m.J. Respir. Crit. Care Med. (1999) 159(2)806.
61. UDOLF M: The reality of drug use in COPD: the European perspective. Chest (.2000) 117:295-325.
62. CALVERLEY PMA, BARNES PJ: Pro/Con editorial: Inhaled corticosteroids arc/arc not beneficial in chronic obstructive pulmonary disease. Am.J. Respir. Crit. Care Med. (2000) l6l(l):341-344.
63. Critical debate on the effectiveness of corticosteroids in COPD.
64. LLEWELLYN-JONES CG, HILL SL, STOCKLEY RA: Effect of flutlcasonc propionatc on neutrophil chemotaxis, Superoxide generation and extracellular protcolytic activity/ vitro. Thorax (199V 49:207-212.
65. LLEWELLYN-JONES CG, HARRIS TA, STOCKLEY RA: Effect of fluticasone propionatc on sputum of patients with chronic bronchitis and emphysema. Am.J. Respir. Crit. Care Med. (1996) 153:616-621.
66. BARNES PJ, ADCOCK IM: Anti-inflammatory actions of steroids: molecular mechanisms. TIPS (1993) 14:436-441.
67. KEATINGS VM, JATAKANON A, WORSDELL YM, BARNES PJ: Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J.
68. Respir. Crit. Care Med. (1997) 155:542-548.
69. CULPITT SV, MAZIAK W, LOUKIDIS S, NIGHTINGALE JA, MATTHEWS JL, BARNES PJ: Effect of high dose inhaled steroid on cells, cytokines and proteascs in induced sputum in COPD. Am. J. Respir. Crit. Care Med. (1999) I60(l):l635-l639.
70. CONFALONIERI M, MAINARDI E, DELIA PORTA R et al: Inhaled corticosteroids reduce ncutrophilic bronchial inflammation in patients with chronic obstructive puhnonary disease. Thorax (1998) 53:583-585.
71. AUFFARTH B, POTSMA DS, DE MONCHY JGR, VAN DE MARK THW, BOORSMA M, KOETER GH: Effects of inhaled budesonide on spiromctric values, reversibility, airway rcsponsiveness and cough threshold in smokers with chronic obstructive pulmonary disease. Thorax (1991) 46:372-377.
72. WATSON A, LIM TK, JOYCE H, PRICE NB: Failure of inhaled corticosteroids to modify bronchoconstrictor or bronchodilator rcsponsiveness in middle aged smokers with mild airflow obstruction. Chest (1992) 101:350-355.
73. KERSTJENS HAM, BRAND PLP, HUGHES MD et al.: A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N. Engl.J. Mod. (1992) 327:1413-1419.
74. First study to indicate that corticosteroids are not effective in COPD.
75. RENKEMA TE, SCHOUTEN JP, KOETER GH, POSTMA DS: Effects of long-term treatment with corticosteroids in COPD. Chest (1996) 109:1156-1162.
76. PAGGIARO PL, DAHLE R, BAKRAN I, FRITH L, HOLLINGWORTH K, EFTHIMIOU J: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet (1998) 351:773-780.
77. BOURBEAU J, ROULEAU MY, BOUCHER S: Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Tlmrax (1998) 53:477-482.
78. VESTBO J, SORENSEN T, LANGE P, BRIX A, TORRE P, VISKUM K: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive puhnonary disease: a randomised controlled trial. Lancet (1999) 353:1819-1823.
79. DOMPELING E, VAN SCHAYCK CP, MOLEMA J, FOLGERING H, VAN GRUNSVEN PM, VAN WEEL C: Inhaled bcclomcthasone improves the course of asthma and COPD. Ear, Respir.J. (1992) 5:945-952.
80. BÜRGE PS: EUROSCOP, ISOLDE and the Copenhagen City Lung Study. Tljorax (1999) 54:287-288.
81. Evaluation of unpublished but important multicentre long-term studies of the clinical effects of inhaled corticosteroids in COPD.
82. BÜRGE PS, CALVERLEY PMA, JONES PW, SPENCER S, ANDERSONJA, MASLEN TK on behalf of the ISOLDE study investigators: Randomised double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive puhnonary disease: the ISOLDE trial Br. Med.J. (2000) 320:1297-1303.
83. This study demonstrated a small reduction in exacerbation rates, but no effect on the rate of decline in FEV]. This concurs with the other cited large, long-term multicentre clinical trials of inhaled steroids in COPD
84. JARAD NA, WEDZICHAJA, BÜRGE PS, CALVERLEY PM: An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir. Med. (1999) 93:161-166.
85. CALLAHAN CM, DITTOS RS, KATZ BP: Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann. Intern. Med. (1991) 114:216-223.
86. CHANEZ P, VIGNOLA AM, O'SHAUGNESSY T et al.: Corticosteroid reversibility in COPD is related to features of asthma. Am.]. Respir. Crit. Care Med. (1997) 155:1529-1534.
87. POSTMA DS, STEENHUIS EJ, VAN DER WEELE LT, SLUITER HJ: Severe chronic airflow obstruction: can cortlcostcroids slow down obstruction? Ear. Respir. J. (1988) 1:22-26.
88. POSTMA DS, PETERS I, STEENHUIS EJ, SLUITER HJ: Moderately severe chronic airflow obstruction. Can corticosteroids slow down obstruction? Eur. Resp. J. (1988) 22-26.
89. SAINT S, BENT S, VITTINGHOFF E, GRADY D: Antibiotics in chronic obstructive pulmonary disease exacerbations. A mcta-analysis.yJ/. (1995) 273:957-960.
90. NIGHTINGALE JA, ROGERS DF: Should drugs affecting mucus properties be used in stable COPD? (2000) Part II: Clinical Evidence: In: Clinical Management of Stable COPD. Similowski T, Whitebw WA, Derenne J-P, Lenfant C(Eds.), Marcel Dekker, Inc., NY, USA. (In Press).
91. AYLWARD M, MADDOCK J, DEWLAND P: Clinical evaluation of acetylcysteine in the treatment of patients with chronic obstructive bronchitis: a balanced double blind trial with placebo control. Eur.J. Respir. Dis. (1980) 6l(Suppl.lll):S81-S89.
92. TODISCO T, POLIDORIR, ROSSIF et al: N-acetylcysteine in subjects with slow pulmonary mucociliary clearance. Eur. J. Respir. Dis. (1985) 66(Suppl. 139):S136-S141.
93. BOMAN G, BACKER U, LARSSON S, MELANDER B, WAHLANDER L: Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur.J. Respir. Dis. (1983) 64:405-415.
94. LUNDBACK B, LINDSTROM M, JONSSON E étal.: Effect of N-acctylcysteine on the decline in lung function in patients with COPD. Eur. Respir. J. (1995) 5:895.
95. ROSE JE, BEHM FM, WESTMAN EC, LEVIN ED, STEIN RM, RIPKA GV: Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine skin patch treatment alone. Clin. Pharmacol. Tber. (1994) 56:86-99.
96. SCHNEIDER NG, OLMSTEAD RE, STEINBERG C, SLOAN K, DAIMS RM, BROWN HV: Efficacy of buspironc in smoking cessation: a placebo-controlled trial Clin. Phannacol. TJxr. (1996) 60:568-575.
97. GOLDSTEIN MG: Bupropion sustained release and smoking cessation./ Clin. Psychiatry(1998) 59:66-72.
98. Important adjunctive therapy for smokers and, by implication, COPD.
99. PAUWELS RA: National and international guidelines for COPD: the need for evidence. G7jes/(2000) 117:205-225.
100. OBA Y, SALZMAN GA, WILLSIE SK: Revaluation of continuous oxygen therapy after initial prescription in patients with chronic obstructive pulmonary disease. Respir. Care(.200O) 45:401-406.
101. LAÇASSE Y, WONG E, GUYATT GH eta!.: Meta-analysis of respiratory rehabilitation In chronic obstructive pulmonary disease, lancet (.1996) 348:1115-1119.
102. SMITH K, COOK D, GUYATT GH et al.: Respiratory muscle training in chronic airflow limitation: a meta-anarysis. Am. Rev. Respir. Dis. (1992) 145:533-539.
103. FITTING JW: Nutritional support in chronic obstructive lung disease. Thorax (1992) 47:141-143.
104. RAHMAN I, MACNEE W: Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radie. Biol. Aled. (1996) 21:669-681.
105. JONES SE, PACKHAM S, HEBDEN M, SMITH AP: Domiciliary nocturnal intermittent positive pressure ventilation in patients with respiratory failure due to COPD: long term follow-up and effect on survival
106. joro.v(1998) 53:495-498.
107. DOYLE RL, MARK JB: Lung volume reduction surgery for the treatment of chronic obstructive pulmonary disease. Adv. Intern. Med. (1998) 43:233-252.